Chronic inflammatory demyelinating polyradiculoneuropathy, usually called CIDP, is a rare autoimmune disorder in which the immune system attacks the protective myelin coating of peripheral nerves, causing progressive weakness and numbness that develops over at least eight weeks. Unlike its acute cousin, Guillain-Barré syndrome, CIDP is a long-haul condition that can follow a relapsing-remitting or steadily progressive course and lead to significant disability if left untreated.1PubMed Central. The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy The good news is that most people respond to treatment, but the path to diagnosis is often frustratingly slow, and the details of management matter a lot for long-term outcomes.
What CIDP Feels Like
The hallmark of CIDP is a gradually building weakness in both the legs and arms, typically starting in the legs and working its way upward. You might notice that climbing stairs becomes harder, that you stumble more, or that gripping a jar lid suddenly takes real effort. Alongside the motor symptoms, most people develop sensory changes: tingling, numbness, or a buzzing sensation in the hands and feet, and sometimes a loss of balance that feels disproportionate to the weakness. Reflexes at the knee and ankle often disappear or become very faint, which is one of the first clinical clues a neurologist looks for.
The timeline sets CIDP apart from many other neuropathies. Symptoms must progress for at least eight weeks to meet diagnostic criteria, and many people report a slower buildup over months. Some experience a relapsing-remitting pattern where symptoms flare, partially improve, and then flare again, while others have a steady decline. A small subset presents acutely enough to initially look like Guillain-Barré syndrome; the distinction becomes clearer if the patient deteriorates after nine weeks from onset or worsens three or more times, at which point long-term maintenance therapy should be considered.2PubMed. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations
Not All CIDP Looks the Same
The “classic” form of CIDP, with symmetric weakness in both proximal and distal muscles plus sensory loss, accounts for most cases. In a large Italian registry, about 82% of patients had this typical presentation.3PubMed. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database The remaining roughly one in five had an atypical variant:
- Distal (DADS): weakness and numbness concentrated in the hands and feet rather than spreading to upper arms and thighs.
- Purely motor: weakness without significant numbness or tingling.
- Lewis-Sumner syndrome: asymmetric involvement, often affecting one limb more than others, which can mimic other conditions like multifocal motor neuropathy.
- Purely sensory: numbness, pain, and balance trouble with minimal or no weakness on exam.
These variants matter for two reasons. First, they can mislead clinicians who are watching for the textbook symmetric pattern, leading to delayed diagnosis. Second, different subtypes sometimes respond differently to treatment. The purely sensory form, for instance, can be particularly tricky to confirm because nerve conduction studies may show subtler abnormalities.
CIDP in Children
CIDP is much rarer in children than adults, but it does occur and has its own personality. In one pediatric series, roughly half the children presented with an atypical variant, most commonly the distal form, rather than the classic symmetric pattern.4PubMed Central. Pediatric CIDP: Diagnosis and Management. A Single-Center Experience Some children also developed additional features not typically seen in adults, such as tremor or involuntary facial movements. The overall prognosis for children tends to be favorable, with about half achieving complete remission, though many require prolonged treatment to get there.
What Drives CIDP
CIDP is an autoimmune condition, meaning the immune system misfires against the body’s own tissue. In this case, the targets are components of the myelin sheath and the structures around peripheral nerve fibers. Immune cells, particularly T cells and macrophages, along with circulating antibodies, infiltrate the nerves and strip away myelin, a process called demyelination.1PubMed Central. The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy Without that insulating sheath, nerve signals slow down or fail altogether, producing weakness and sensory loss.
What triggers the immune system to turn on its own nerves remains unclear. Unlike some autoimmune diseases linked to specific infections or genetic markers, CIDP usually appears without an obvious precipitating event. The complement system, an arm of innate immunity that amplifies antibody-driven damage, plays a role in nerve destruction and has become a focus of new drug development.5PubMed Central. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
A subset of patients carry specific antibodies against a nerve protein called neurofascin-155. These antibodies, found in about 7% of people diagnosed with CIDP, tend to mark a distinct clinical picture: patients are often younger, have prominent tremor, and may respond differently to standard immunoglobulin therapy.6PubMed Central. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy Identifying these antibodies is clinically useful because it can guide treatment choices early on.
Getting the Diagnosis Right
Diagnosing CIDP relies on a combination of clinical evaluation, nerve conduction studies, and sometimes additional tests. The European Academy of Neurology and Peripheral Nerve Society maintain joint guidelines that form the most widely used diagnostic framework.7PubMed Central. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision The core idea is straightforward: nerve conduction studies should show patterns consistent with demyelination, such as slowed conduction velocities, prolonged response times, or conduction block where a signal weakens across a nerve segment.
A lumbar puncture often supports the diagnosis. The spinal fluid in CIDP typically shows elevated protein without a significant increase in white cells, a pattern that points to inflammation around the nerve roots. MRI can also help, particularly imaging of the lumbar spine. In one study, enhancement of the cauda equina nerve roots on MRI was seen in about 69% of CIDP patients and in none of the controls.8PubMed Central. MRI of the cauda equina in CIDP: clinical correlations While those MRI findings did not correlate with disease severity, they can be helpful when the nerve conduction picture is ambiguous.
CIDP is frequently confused with other conditions. Hereditary neuropathies like Charcot-Marie-Tooth disease can produce similar nerve conduction patterns. Diabetic neuropathy, discussed in more detail below, can mask CIDP entirely. For much of the 20th century, CIDP was not even recognized as a distinct entity; its features were lumped together with Guillain-Barré syndrome and hereditary neuropathies until the 1970s, when clearer diagnostic boundaries were established.9JAMA Neurology. Chronic Inflammatory Demyelinating Polyradiculoneuropathy
First-Line Treatments
Three treatments form the backbone of CIDP management: corticosteroids, intravenous or subcutaneous immunoglobulin, and plasma exchange. All three have reasonable evidence behind them, and the choice often depends on a mix of clinical factors, patient preference, and practical constraints like cost and access.
Corticosteroids
Steroids remain a common and affordable first-line option. A retrospective study comparing three different steroid regimens found that about 60% of patients responded, with no significant difference in effectiveness among daily oral prednisone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.10PubMed Central. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone Among those who responded, about 61% stayed in remission over a median follow-up of roughly four and a half years, and the probability of maintaining a five-year remission was around 55%. That is a meaningful result for a relatively inexpensive treatment.
A separate study using pulsed oral steroids reported that all treated patients improved and 60% achieved off-treatment remission, though steroid-induced bone loss remained a concern, especially in older patients.11PubMed. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids Side effects from daily oral prednisone, particularly weight gain and a puffy facial appearance, affected about 58% of patients in one comparative study. Switching to intermittent intravenous methylprednisolone brought that figure down to around 19%.12JAMA Neurology. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone The takeaway for patients is that how steroids are dosed matters as much as whether they are used at all.
Immunoglobulin Therapy
Intravenous immunoglobulin (IVIg) delivers pooled antibodies from healthy donors and is one of the most widely used treatments for CIDP. It works relatively quickly, often producing noticeable improvement within weeks, and avoids the bone loss and metabolic effects associated with long-term steroids. For maintenance therapy, subcutaneous immunoglobulin (SCIg), which patients can self-administer at home, has proven effective. In the large PATH trial, relapse rates dropped substantially with SCIg compared to placebo: about 63% of placebo patients relapsed versus 39% on a lower dose and 33% on a higher dose.13The Lancet Neurology. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled trial
The main drawback of immunoglobulin therapy is cost. In a claims database analysis, the mean two-year treatment cost for patients on IVIg alone was roughly $120,000, compared to about $3,100 for steroids alone.14PubMed Central. Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis That enormous gap influences prescribing patterns: in that same dataset, more than half of newly diagnosed patients were started on steroids, and about a quarter received IVIg. For many patients, insurance authorization and drug supply are ongoing hurdles.
Plasma Exchange
Plasma exchange, or plasmapheresis, physically removes circulating antibodies from the blood. If the autoimmune hypothesis is correct, clearing those antibodies should be beneficial, and clinical experience supports that logic.15PubMed Central. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy In practice, plasma exchange is often used when rapid improvement is needed, such as during a severe relapse, or when immunoglobulin and steroids have not worked well. It requires repeated sessions at an infusion center, which makes it less convenient for long-term maintenance than home-administered SCIg or oral steroids.
When Standard Treatments Fall Short
Most people with CIDP respond to at least one of the three first-line options, but a meaningful minority does not. Estimates suggest that 20 to 30% of patients respond poorly, and roughly 15% remain refractory to all standard treatments.16PubMed Central. Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy For these patients, clinicians turn to immunosuppressant medications like rituximab, mycophenolate mofetil, or cyclophosphamide, all of which have shown benefit in some refractory cases.
Before labeling someone as truly refractory, though, it is worth verifying the diagnosis. A patient who does not respond to any first-line therapy may have been misdiagnosed: hereditary demyelinating neuropathies, multifocal motor neuropathy, or neuropathy associated with a blood-cell cancer can all mimic CIDP. Revisiting the nerve conduction studies, checking for specific antibodies, and sometimes repeating a nerve biopsy are all part of the workup for treatment-resistant cases.
Why Early Treatment Matters
The damage CIDP causes is not limited to myelin. Over time, the underlying nerve fibers themselves, the axons, begin to degenerate. This axonal loss is what ultimately drives permanent disability. A prospective study found that disability in CIDP correlated far more strongly with markers of axonal damage than with markers of demyelination, and this relationship held across disease subtypes and stages.17PubMed. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages
The practical implication is that delaying treatment gives axons time to die, and unlike myelin, axons do not regenerate well. Research has found a clear relationship between the delay from symptom onset to treatment initiation and the extent of long-term axonal loss and disability.18PubMed Central. Axonal loss at time of diagnosis as biomarker for long‐term disability in chronic inflammatory demyelinating polyneuropathy Prompt treatment reduces the risk of irreversible nerve damage. This evidence underscores why the frequently long road to a CIDP diagnosis is more than an inconvenience; it can meaningfully worsen outcomes.
CIDP and Diabetes
Diabetes complicates CIDP in both directions. People with diabetes are more likely to develop peripheral neuropathy from the diabetes itself, and that pre-existing nerve damage can obscure the clinical and electrical signs of CIDP. Superimposed axonal damage from diabetic neuropathy can muddy nerve conduction studies, and elevated spinal fluid protein, which normally supports a CIDP diagnosis, can also be seen in diabetic neuropathy.19PubMed Central. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
The result is that CIDP in people with diabetes tends to be diagnosed later and often presents with greater disability by the time treatment starts.20PubMed. The overlap of diabetic and inflammatory neuropathies: Epidemiology, possible mechanisms, and treatment implications The encouraging finding is that response rates to standard CIDP therapies are comparable whether or not the patient has diabetes. In fact, one review noted a response rate above 80% to first-line therapies regardless of diabetes status, though patients with diabetes often arrived at treatment in worse shape because of delayed referral and the added axonal damage from their underlying neuropathy.21PubMed Central. CIDP and other inflammatory neuropathies in diabetes — diagnosis and management If you have diabetes and notice new or worsening weakness on top of existing numbness, it is worth asking your neurologist whether CIDP should be on the differential.
Living with CIDP and Managing Function
Even with effective treatment, many people with CIDP live with some degree of residual weakness or sensory loss. Rehabilitation becomes an important piece of the puzzle. Physical therapy aimed at strengthening weakened muscles, improving balance, and maintaining range of motion can make a meaningful difference in day-to-day function. Occupational therapy helps with fine motor tasks that become harder when hand strength and sensation are compromised.
Gait problems are common. Depending on the pattern of weakness, different orthotic strategies apply. Distal weakness, which affects the feet and ankles, often responds well to ankle-foot orthoses that prevent foot drop and stabilize the ankle during walking. Proximal weakness in the hips and thighs may require gait aids like walkers or canes. Sensory disturbance alone can destabilize walking even when muscle strength is adequate, and the orthotic approach in that case focuses on proprioceptive support rather than bracing against weakness.22PubMed Central. Approach to gait disorders and orthotic management in adult onset neuromuscular diseases
Fatigue is a widely reported but under-discussed symptom. Many people with CIDP describe an exhaustion that goes well beyond what the degree of weakness would predict. This fatigue does not always improve with immunotherapy and may need to be addressed separately through pacing strategies, energy conservation techniques, and sometimes medication.
Emerging Therapies
The treatment landscape for CIDP is shifting. Two categories of new drugs are drawing the most attention: neonatal Fc receptor (FcRn) blockers and complement inhibitors.16PubMed Central. Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy
FcRn blockers work by accelerating the breakdown of circulating IgG antibodies, which includes the pathological autoantibodies driving nerve damage. Several agents in this class are in clinical trials for CIDP, and their appeal lies in the potential to offer the benefits of immunoglobulin therapy without the cost and supply constraints of pooled donor immunoglobulin products.
Complement inhibitors target a different part of the immune cascade. Riliprubart, a monoclonal antibody that blocks the classical complement pathway, has shown preliminary promise. In early phase 2 data, 88% of patients already on standard therapy improved or remained stable after switching to riliprubart, and 44% showed outright improvement. Among patients who had been refractory to standard treatment, half responded favorably.23Journal of Neurology, Neurosurgery & Psychiatry. Novel therapies in CIDP These are early-stage numbers and should be interpreted cautiously, but they are encouraging, particularly for the refractory population where options are currently limited.
The rationale for complement inhibition in CIDP is grounded in pathology studies showing complement deposits on damaged nerve fibers and evidence that complement activation drives both direct nerve cell destruction and the recruitment of macrophages that strip away myelin.5PubMed Central. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies Targeting this pathway while leaving other immune defenses largely intact could, in theory, offer more precise treatment with fewer side effects than broad immunosuppression. Whether that theory holds up in larger, longer trials is the question the next few years of research should answer.